US FDA approves Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for unresectable or metastatic hepatocellular carcinoma (HCC) in patients who have not received previous systemic therapy

Approval based on Phase 3 trial which showed atezolizumab with bevacizumab decreased relative risk of death by 42% and reduced relative risk of the cancer getting worse or death by 41%, compared with sorafenib. Potential for a UK license extension is currently unknown.


Biospace Inc.